RESEARCH CONTEXT · DOSES
CJC-1295 Doses Used in the Research Literature
What was administered, to which species, at which dose, by which route — and where the line falls between a pharmacokinetic probe and a human protocol that does not exist.
CJC-1295 Doses Used in the Research Literature
There is no established human dose for CJC-1295. Searches for CJC-1295 dosage return fixed-microgram numbers that the published record does not support; what the literature actually provides is a small set of doses used as research probes, and the most useful thing this page can do is state them precisely and mark the boundary between them and the fixed-microgram 'protocols' that circulate online.
The human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1][3]. Teichman and colleagues used 30 and 60 µg/kg to characterize the GH and IGF-1 time courses and the 5.8- to 8.1-day half-life [1]; Ionescu and Frohman used 60 and 90 µg/kg to measure the +7.5-fold basal GH and +45% IGF-1 response and to confirm preserved pulsatility [3]. These are weight-normalized doses given to healthy volunteers in controlled studies, described here as research context, not as guidance.
The Preclinical Dose, and the Protocols That Are Not Trials
The preclinical dose comes from the GHRH-knockout mouse study, where 2 µg of CJC-1295 per dose was given at 24-, 48-, or 72-hour intervals; once every 24 hours fully normalized growth, while less frequent dosing was progressively inferior [4]. That experiment establishes a dosing-interval principle for the long-acting analog in a mouse model — not a human dose.
The fixed-microgram figures common in community and clinic 'protocols' — for the no-DAC Modified GRF 1-29 and for CJC-1295/ipamorelin pairings, often quoted around 100 to 300 µg — are not derived from controlled human trials. They are conventions, not trial outputs, and this site does not present them as doses to follow. The only human numbers grounded in published studies are the 30/60/90 µg/kg pharmacokinetic doses [1][3].
How much CJC-1295 should I take?
There is no established human dose. Published human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1][3]; circulating fixed-dose 'protocols' are not derived from controlled human trials. This is described for research context only.
How much CJC-1295 / ipamorelin should I take?
No controlled human trial defines a CJC-1295/ipamorelin dose. Community 'protocols' commonly cite fixed microgram doses, but these are not trial-derived; the literature establishes only the two-receptor synergy rationale, not a regimen [1].
Routes, Handling, and Stability in the Research
Subcutaneous injection was the primary route in CJC-1295 studies; early GRF(1-29) pharmacokinetic work also used intravenous administration. Oral bioavailability is negligible, as expected for a peptide of this size. The four substitutions confer DPP-IV and protease resistance, and DAC conjugation confers the multi-day duration [1][2].
How is CJC-1295 reconstituted in research handling?
As a lyophilized peptide, CJC-1295 is reconstituted with bacteriostatic water and refrigerated in laboratory handling; oral bioavailability is negligible. This describes laboratory handling, not human-use instructions.
What route was used in studies?
Subcutaneous injection was the primary route in CJC-1295 studies [1][3], with early GRF(1-29) pharmacokinetic work also using intravenous administration. This states the route used in the research, not administration guidance.
Why a Single Dose Lasts Days
The dosing intervals seen in the research follow directly from the pharmacokinetics. Because the DAC form binds serum albumin covalently, a single subcutaneous dose elevates growth hormone for six days or more and IGF-1 for nine to eleven days [1] — which is why the GHRH-knockout-mouse study found once-daily dosing sufficient and less-frequent dosing progressively inferior [4]. Duration, not per-dose amount, is the variable the long-acting design was built to control.
For the full pharmacokinetic comparison between the long-acting DAC form and the short-acting no-DAC Modified GRF (1-29), see the CJC-1295 DAC vs no-DAC page; for the citations behind every figure here, see the full reference list.